Then we used three tumor cell lines (K562, K562-CD19 and NALM-6) for the validation of the CD19 antigen specific killing of the engineered anti-CD19 scFv TCRγδ T cells (Fig. 6B). This evidence concerns the gene CD19 and neoplasm.